Arrowhead CEO: We feel 'great' about the drug
November 10, 2014 at 18:55 PM EST
Arrowhead Research CEO Chris Anzalone said the company's hepatitis B drug, ARC-520, has potential, and in increased doses, it may provide the efficacy investors are looking for.
